, Volume 29, Issue 2, pp 112–118 | Cite as

Monoklonale Antikörper in der Onkologie



Die Behandlung mit monoklonalen Antikörpern stellt eine zentrale Säule in der modernen Krebstherapie dar. In Deutschland sind derzeit 11 unkonjugierte Antikörper (Catumaxomab, Rituximab, Cetuximab, Bevacizumab, Eculizumab, Alemtuzumab, Trastuzumab, Pertuzumab, Ofatumumab, Panitumumab und Ipilimumab) sowie 2 konjugierte monoklonale Antikörper (90Yttrium-Ibritumomab-Tiuxetan und Brentuximab Vedotin) zur antitumoralen Immuntherapie zugelassen. Eine bemerkenswerte Entwicklung in der spezifischen Antitumorimmuntherapie stellen immunmodulatorische (Checkpoint-)Antikörper dar, wie z. B. Anti-CTLA-4- und Anti-PD-1- bzw. Anti-PD-L1-Antikörper, die vielversprechende klinische Erfolge verzeichnen.


Hämatologische Erkrankungen Tumoren Monoklonale Antikörper Krebstherapie Immunmodulation 

Monoclonal antibodies in oncology



In current treatment strategies for patients with hematological malignancies and solid tumors, monoclonal antibody therapy has evolved into one of the most successful and most important therapeutic concepts. To date 11 unconjugated monoclonal antibodies (catumaxomab, rituximab, cetuximab, bevacizumab, eculizumab, alemtuzumab, trastuzumab, pertuzumab, ofatumumab, panitumumab and ipilimumab) and 2 conjugated monoclonal antibodies (90Yttrium-ibritumomab tiuxetan and brentuximab vedontin) are currently approved for anti-tumor immunotherapy in Germany. The remarkable development of immunomodulatory (checkpoint) antibodies, such as anti-CTLA-4, anti-PD1 and anti-PD-LA has recently achieved very promising clinical success.


Hematologic malignancies Neoplasms Monoclonal antibodies Cancer treatment Immunomodulation 


Einhaltung ethischer Richtlinien

Interessenkonflikt. J. Nolting, D. Wolf und B. Brossart geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.


  1. 1.
    Brahmer JR et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    McDermott D et al (2013) Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 24(10):2694–2698PubMedCrossRefGoogle Scholar
  3. 3.
    Bargou R et al (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891):974–977PubMedCrossRefGoogle Scholar
  4. 4.
    Saini KS et al (2011) Rituximab in Hodgkin lymphoma: is the target always a hit? Cancer Treat Rev 37(5):385–390PubMedCrossRefGoogle Scholar
  5. 5.
    Wierda WG et al (2011) Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 118(19):5126–5129PubMedCrossRefGoogle Scholar
  6. 6.
    Goede V et al (2014) Obinutuzumab plus Chlorambucil in patients with CLL and coexisting conditions. N Engl J Med (Epub ahead of print). DOI 10.1056/NEJMoa1313984Google Scholar
  7. 7.
    Bokemeyer C et al (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48(10):1466–1475PubMedCrossRefGoogle Scholar
  8. 8.
    Bang YJ et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697PubMedCrossRefGoogle Scholar
  9. 9.
    Minckwitz G von et al (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366(4):299–309CrossRefGoogle Scholar
  10. 10.
    Bear HD et al (2012) Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366(4):310–320PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Sebastian M et al (2007) Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunol Immunother 56(10):1637–1644PubMedCrossRefGoogle Scholar
  12. 12.
    Topp MS et al (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29(18):2493–2498PubMedCrossRefGoogle Scholar
  13. 13.
    Topp MS et al (2012) Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120(26):5185–5187PubMedCrossRefGoogle Scholar
  14. 14.
    Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331(6024):1565–1570PubMedCrossRefGoogle Scholar
  15. 15.
    Pages F et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654–2666PubMedCrossRefGoogle Scholar
  16. 16.
    Topalian SL et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Wolchok JD et al (2013) Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann NY Acad Sci 1291:1–13PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Robert C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526PubMedCrossRefGoogle Scholar
  20. 20.
    Camacho LH et al (2009) Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27(7):1075–1081PubMedCrossRefGoogle Scholar
  21. 21.
    Kirkwood JM et al (2010) Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 16(3):1042–1048PubMedCrossRefGoogle Scholar
  22. 22.
    Ribas A et al (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31(5):616–622PubMedCrossRefGoogle Scholar
  23. 23.
    Hamanishi J et al (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104(9):3360–3365PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Hino R et al (2010) Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116(7):1757–1766PubMedCrossRefGoogle Scholar
  25. 25.
    Wolchok JD et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122–133PubMedCrossRefGoogle Scholar
  26. 26.
    Genova C et al (2012) Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. Expert Opin Biol Ther 12(7):939–948PubMedCrossRefGoogle Scholar
  27. 27.
    Royal RE et al (2010) Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33(8):828–833PubMedCrossRefGoogle Scholar
  28. 28.
    Slovin SF et al (2013) Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 24(7):1813–1821PubMedCrossRefGoogle Scholar
  29. 29.
    Sprinzl MF, Galle PR (2013) Facing the dawn of immunotherapy for hepatocellular carcinoma. J Hepatol 59(1):9–10PubMedCrossRefGoogle Scholar
  30. 30.
    Yang JC et al (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30(8):825–830PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Medizinische Klinik III für Hämatologie, Onkologie und RheumatologieUniversitätsklinikum BonnBonnDeutschland

Personalised recommendations